Comparing the current results to its competitors, Accustem Sciences Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Accustem Sciences Inc 's competitors' average revenue growth of 16.7 %, achieved in the same quarter.
Accustem Sciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 48.57 %
Accustem Sciences Inc 's Comment on Competition and Industry Peers
The company operates in a competitive market for multi-gene prognostic assays used to predict the risk of recurrence in luminal (ER+/HER2-) breast cancer patients. It faces challenges related to obtaining and maintaining patent protection, as insufficient patent coverage could allow competitors to develop and commercialize similar products and technologies. The company depends on third parties for certain resources and services and relies on key individuals within its management team, Board of Directors, and scientific advisors.
Mainz Biomed N v operates on a business model focused on the development and commercialization of innovative biomedical solutions. They leverage their expertise in research, development, and manufacturing to create novel biopharmaceutical products with strong market potential. Through strategic partnerships and collaborations, they aim to bring their cutting-edge products to the market, ultimately improving healthcare outcomes.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Sources:
Accustem Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Accustem Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
